Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis,International Immunopharmacology

当前位置： X-MOL 学术 › Int. Immunopharmacol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis
International Immunopharmacology ( IF 4.8 ) Pub Date : 2020-12-25 , DOI: 10.1016/j.intimp.2020.107280
Xiaochun Lin , Kunpeng Lin , Chunxuan Lin , Taisheng Liu , Mingchen Ba , Yunqiang Tang , Jialang Wang , Lixia Zhou , Jiakang Wang , Congqin Xiao

Objective

The prognostic role of programmed death ligand-2 (PD-L2) expression in lung cancer has been widely studied, however, the results are controversial. Accordingly, we investigated the prognostic and clinicopathological value of PD-L2 in patients with lung cancer in this meta-analysis.

Methods

Relevant studies were systematically searched in the PubMed, Web of Science, EMBASE, ClinicalTrials.gov., Scopus, and Cochrane Library until July 10, 2020. The hazard ratio (HR), odds ratio (OR), and their corresponding 95% confidence intervals (CIs) were calculated.

Results

Thirteen studies with 3107 participants were included. High PD-L2 expression was associated with poor overall survival (OS) (HR 1.248, 95% CI: 1.071–1.455, p = 0.004) and worse disease-free survival (DFS)/progression-free survival (PFS)/relapse-free survival (RFS) (HR 1.224, 95% CI: 1.058–1.417, p = 0.007) in lung cancer. Furthermore, unfavorable OS was found in lung adenocarcinoma (HR 1.349, 95% CI: 1.051–1.731, p = 0.019), but not in other pathological types (HR 1.192, 95% CI: 0.982–1.447 p = 0.076) with higher PD-L2 expression in our subgroup analysis. Concerning the clinicopathological characteristics, high PD-L2 expression was associated with smoking (OR 0.725, 95% CI: 0.591–0.890, p = 0.002) and PD-L1 (OR 1.607, 95% CI:1.115–2.314, p = 0.011) and vascular invasion (OR 1.500, 95% CI: 1.022–2.203, p = 0.039).

Conclusion

PD-L2 overexpression might predict a poor prognosis in lung cancer patients after surgery. PD-L2 expression might be a potential biomarker for PD-1/PD-L1-targeted immunotherapy in lung cancer, which should be investigated in future studies.

中文翻译：

PD-L2在肺癌中的预后和临床病理价值：一项荟萃分析

目的

程序性死亡配体2（PD-L2）表达在肺癌中的预后作用已得到广泛研究，但结果尚存争议。因此，我们在这项荟萃分析中调查了PD-L2在肺癌患者中的预后和临床病理价值。

方法

直到2020年7月10日，才在PubMed，Web of Science，EMBASE，ClinicalTrials.gov。，Scopus和Cochrane图书馆中系统地搜索相关研究。危险比（HR），优势比（OR）及其相应的95％置信度计算间隔（CI）。

结果

包括13107名参与者的13项研究。高PD-L2表达与较差的总体生存率（OS）（HR 1.248，95％CI：1.071–1.455，p = 0.004）和较差的无病生存期（DFS）/无进展生存期（PFS）/复发相关肺癌的平均生存时间（RFS）（HR 1.224，95％CI：1.058–1.417，p = 0.007）。此外，在肺腺癌中发现OS不良（HR 1.349，95％CI：1.051–1.731，p = 0.019），但在其他病理类型（HR 1.192，95％CI：0.982–1.447 p = 0.076）中没有发现-L2表达在我们的亚组分析中。关于临床病理特征，高PD-L2表达与吸烟相关（OR 0.725，95％CI：0.591–0.890，p = 0.002）和PD-L1（OR 1.607，95％CI：1.115–2.314，p = 0.011）和血管侵犯（OR 1.500，95％CI：1.022–2.203，p = 0.039）。